This article is more than 5 years old. Information may no longer be current.

Positive early results seen with iontophoretic EGP-437 in cataract surgery patients

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A phase 1b/2a trial of iontophoretic EGP-437 for the treatment of ocular inflammation and pain in post-surgical cataract patients has shown positive results, EyeGate Pharmaceuticals announced in a press release.

The multicenter, open-label trial included 30 patients who had undergone cataract surgery with implantation of a posterior chamber IOL. Subjects received EGP-437 at 4.5 mA-min or 14 mA-min or a placebo at 14 mA-min.

Patients in both EGP-437 groups had a reduction in anterior chamber cell count, whereas the placebo group required 80% of patients to be rescued before day 14. Those who received EGP-437 at 4.5 mA-min had the greatest benefit.

“Patients receiving EGP-437 at both dosing levels experienced reduced pain at all time points, with 70% of patients having a pain score of zero as early as day 1 versus the placebo cohort where only 10% achieved a pain score of zero at day 1,” the release said.

The company is planning to begin a randomized, double-masked, placebo-controlled study on iontophoretic EGP-437 in cataract surgery patients in the first half of 2017.